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Abstract
Population ageing is one of the most significant social transformations of the 
twenty-first century. The increase in average life expectancy was a successful chal-
lenge achieved in the modern world. However, nowadays a new challenge arises for 
all society: achieving a better quality of life for increasing people’s life. The comor-
bidities associated with ageing make elderly prone to polypharmacy. On the other 
hand, physiological and cognitive changes interfere with drugs’ pharmacodynamics 
and pharmacokinetics contributing to drug-related problems which have been 
reported to account for a large percentage of emergency treatment and hospitaliza-
tions of older people, increasing the costs with health in the most aged regions. In 
order to reduce the use of potentially inappropriate medicines in this population, 
strategies and tools have been developed in recent years to assess the appropriate-
ness medication use in the elderly.
Keywords: polypharmacy, elderly, pharmacodynamics, pharmacokinetics, 
potentially inappropriate medication
1. Introduction
Ageing is an inevitable process characterized by declining functions and 
increased susceptibility to certain diseases. Biologically, ageing results from a 
variety of molecular and cellular damage over time, leading to a gradual decrease in 
physical and mental capacity, increasing the risk of illness and death [1]. The fragil-
ity acquired by the elderly population with ageing is related to the gradual decrease 
of the physiological reserve and the failure of the homeostatic mechanisms. Thus, 
a cumulative decline is promoted in several physiological systems, and there is an 
exhaustion of the body’s reserves, starting to have a greater vulnerability to changes 
in health status [2]. The mechanisms associated with ageing are determined by 
environmental factors but also by genetic factors, which regulate the expression of 
genes that can be especially important for this process [3].
With ageing, many chronic diseases arise, requiring the use of a higher number 
of drugs. Polypharmacy, defined as the use of five or more drugs, is a significant 
public health problem, particularly in the older adults, since it is responsible for 
the increase of adverse drug reactions (ADR) and, frequently, for the rise of the 
morbidity and mortality in this population [4]. There are many other important 
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issues related to the problem of polypharmacy, such as the interaction between 
drugs, organization and adherence to treatment [4].
Through the normal ageing process, changes occur with impact on the pharmaco-
dynamics and pharmacokinetics of drugs. These changes may be related to the func-
tion of particular organs, homeostatic mechanisms and also to the ability to respond 
to specific receptors, causing greater vulnerability and susceptibility to ADR in older 
patients [5] frequently associated with the use of potentially inappropriate medica-
tion (PIM) in this population [6]. The inappropriate prescription in older patients 
occurs when the risk of adverse effects exceeds the clinical benefit, especially when 
there are more effective alternatives available [7]. The use of PIM is a public health 
challenge because it has high prevalence rates in different health contexts [8].
Although older adults are the primary consumers of medicines, the truth is 
that clinical trials are usually carried out on younger people, and the physiological 
changes that occur with ageing are not considered. With the rise of older people in 
the world, the needs associated with the resources of health systems will continue to 
increase, and several challenges will arise.
Over the past few years, to reduce the use of PIM in the older population, strate-
gies and tools of explicit and implicit criteria have been developed to evaluate the 
appropriateness of medication use in the older patients. These criteria are useful 
tools for clinical practice, as a support for clinical decision.
2. Physiological and pharmacological changes in the elderly
The normal ageing process implies the occurrence of several physiological, 
biological, physical and psychological changes, which can affect the elderly 
patient’ quality of life and modify the ability to reach the best health outcomes 
[9]. The changes caused by ageing are associated with complex pathophysiology, 
variability in organ function and the presence of comorbidities, specific to this 
population [2]. When young, the human body has a sizeable physiological reserve 
to sustain the function of most organs. However, in early adulthood, the first 
physiological changes that can affect drug effects begin to occur, and the decline 
of cellular activity becomes a gradual and continuous process. In older adults, this 
reserve is increasingly diminished with decreasing in homeostatic mechanisms 
activity [10].
All of these factors contribute to the frailty of older adults making them more 
prone to drug-related problems. Most older people can experience significant 
changes in drug pharmacokinetics and pharmacodynamics due to age-related physi-
ological changes and become more susceptible and vulnerable to adverse effects [7].
2.1 Age-related changes in pharmacokinetics
The bioavailability of a drug depends on many factors and all stages of pharma-
cokinetics (absorption, distribution, metabolism and excretion) and can be modi-
fied with ageing [9, 11]. A summary of the main pharmacokinetics changes can be 
consulted in Table 1.
There are several available routes of administration. However, the most common 
is the oral route. Although ageing is associated with decreased gastric emptying 
and peristalsis, in the absence of pathology, the absorption of most drugs does not 
decrease with age [9]. However, the presence of pathologies that affect the gastro-
intestinal organs can affect absorption. Furthermore, food intake can also affect 
drugs’ absorption. The fraction of the drug dose administered that reaches the 
bloodstream, after oral administration, can be influenced by several other factors, 
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such as gastric pH, gastrointestinal motility, intestinal permeability and mucosal 
integrity, function and expression of drug carriers and gastrointestinal blood 
flow [11].
Drugs absorption after intramuscular or subcutaneous administration can be 
modified in older patients because there is a reduction in blood perfusion of the 
tissues [12].
After absorption, the drug enters the bloodstream and is distributed through 
the body. The distribution will influence the amount of active substance available to 
prosecute an effect at a specific target. Factors such as the extent of binding to tissues 
and plasmatic proteins, changes in body composition and protein synthesis can affect 
the distribution of drugs [11]. The volume of distribution can be affected by the pro-
portions of lean body mass and fat body mass. With ageing, there is a reduction in the 
amount of body water and an increase in fat, so there are changes in the distribution 
of drugs that depend on lipid solubility. Also, the half-life of a drug increases with the 
volume of distribution. Thus, a decrease in the volume of distribution for hydrophilic 
drugs results in higher plasma concentrations and a lower half-life in older patients. 
Some examples are drugs such as digoxin and theophylline. As the volume of distri-
bution increases, the half-life of liposoluble drugs increases, affecting, for example, 
long-acting benzodiazepines that can accumulate in the body [12].
Metabolism consists of converting an active substance in simpler and more polar 
substances, called metabolites. These metabolites are inactive or have modified 
activity. In the case of prodrugs, metabolism is necessary to convert the prodrug 
in an active drug. Therefore, hepatic metabolism is essential for the elimination of 
drugs from the body. Hepatic metabolism depends on hepatic blood flow, the trans-
port of the drug from the blood to the hepatocytes and the ability to metabolize the 
drug [11]. It can be difficult to predict changes in liver metabolism for each patient. 
In addition to age, the nutritional status of the elderly also affects the rate of 
metabolism of the drug [12]. Moreover, the increase of inflammatory conditions in 
older adults can compromise the enzymes associated with the metabolism of many 
Pharmacokinetics Physiological changes Drug examples
Absorption Increased gastric pH
Decreased gastrointestinal motility
Decreased intestinal permeability





Distribution Decreased lean body mass
Increased fat body mass
Decreased body water
Benzodiazepines
Metabolism Decreased liver volume
Decreased blood flow
Decreased hepatic clearance rates
Propranolol
Morphine
Excretion Reduced renal blood flow
Decreased glomerular filtration rates
Increased urea excretion
Decreased creatinine production










ACEI, angiotensin conversion enzyme inhibitors; ARBs, angiotensin II receptor blockers; NSAIDs, nonsteroidal 
anti-inflammatory drugs.
Table 1. 
Impact physiological changes and pharmacokinetics in older adults [9, 11–13].
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drugs. Frailty is associated with higher inflammatory markers and a reduction in 
the activity of esterases (enzymes class that catalyse hydrolysis reactions) [5].
With ageing, the composition of gut microbiome also changes. Intestinal 
bacteria play a role in the metabolism of drugs as they, being mostly anaerobic, 
participate in chemical reactions of reduction and hydrolysis of molecules. The 
changes caused by this phenomenon occur mainly in frailty older adults and long-
term nursing homes residents. They have a decreased enzyme induction capacity, 
which can lead to an increase in genetic silencing with age. Also, external factors 
such as exposure to environmental contaminants are responsible for altering gene 
expression. These changes reflect the differential biological ageing [5].
Most drugs are eliminated through the kidneys, and in older adults, the ability 
to concentrate urine is reduced, consequently, there is a need for a higher amount 
of urine to excrete the same amount of toxic waste compared to young adults. The 
decline in renal function is mainly due to the decrease in the glomerular filtration 
rate (GFR) and the reduction in renal blood flow. With ageing, the decline in glo-
merular filtration is quite evident. The decreased in renal function increases the risk 
of ADR, and therefore, special attention should be given when prescribing, to older 
patients, drugs excreted by kidneys. For drugs that have a narrow therapeutic index 
and are excreted through the kidneys, such as digoxin, metformin and lithium, it is 
especially important to adjust and monitor the treatment [12].
This decrease in GFR can be explained by an increase in urea excretion and a 
reduction in creatinine production in older adults. The renal plasma flow is reduced 
by 50%, and the kidney’s ability to increase baseline GFR by at least 20% (the renal 
reserve) also decreases significantly with ageing [13].
Sodium reabsorption is reduced in the older adults, and drugs that promote the 
excretion of salt and water, such as thiazides and loop diuretics, can induce hypo-
natraemia, hypovolaemia and renal failure. Also, renal excretion of potassium is 
significantly reduced with ageing, so drugs such as angiotensin-converting-enzyme 
inhibitor (ACEI), angiotensin II receptor blockers (ARBs), aliskiren, digoxin, 
potassium-sparing agents, beta-blockers and nonsteroidal anti-inflammatory drugs 
(NSAIDs) can induce hyperkalaemia [13].
2.2 Age-related changes in pharmacodynamics
Age-related pharmacodynamic changes may also occur. However, these are more 
difficult to study than pharmacokinetic changes because there is low evidence of the 
mechanism underlying these changes.
Many response measures are subjective and can be influenced by several factors. 
These changes represent how drugs react in the body after absorption. The central ner-
vous system (CNS) and the cardiovascular system, as well as the homeostatic mecha-
nisms, are the most affected with the ageing process. Since most medicines used by the 
older adults have strong anticholinergic properties, the principal ADR that occur in 
this population are confusion, drowsiness and an increased risk of falls and fractures 
[14]. Due to all the physiological changes, an older adult’s ability to recover from an 
illness is often diminished, and symptoms may remain partially for a long time.
Age-related pharmacodynamic changes are associated with receptors (number, 
activity and expression) and with the ability to signal transduction and changes in 
homeostatic mechanisms [15].
Thus, in the older adults, there is an impaired circulatory response, an increased 
risk of falls and fractures, changes in thermoregulation mechanisms, laryngeal reflexes 
compromised with increased risk of aspiration or pneumonia, dehydration and bleed-
ing due to changes in vascular stability and impaired cognitive ability. Therefore, drugs 
with sedative effects can considerably increase the risk of ADR in older patients [16].
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Considering the drugs that act in the CNS, there is an increased sensitivity to the 
action of benzodiazepines, which can cause a high degree of sedation and impaired 
psychomotor performance in older adults, making them more favourable to the 
occurrence of falls and fractures. With increasing age, the ability to respond to anti-
psychotic drugs also increases, so there is an increased risk of anticholinergic and 
extrapyramidal effects, orthostatic hypotension and adverse cerebrovascular effects. 
The increase in the response capacity to antidepressants also increases the risk of 
anticholinergic effects in the elderly, being responsible for causing gastrointestinal 
bleeding and hyponatraemia. These population also have an increased sensitivity to 
intravenous and inhaled anaesthetic and opioid medications, with an increased risk 
of respiratory depression and reduced tolerability to these drugs. Furthermore, with 
ageing, there is an increased sensitivity to the adverse effects caused by lithium, 
increasing the risk of neurotoxic effects in these population [10, 17].
Concerning drugs that act on the cardiovascular system, the main pharmacody-
namic changes associated with age are related to the reduction of the baroreceptor 
response to low blood pressure and the increase in the sinoatrial suppressive effect, 
interfering with the administration of calcium channel blocker drugs, causing 
an effect that can lead to the occurrence of orthostatic hypotension, falls and a 
decrease in heart rate. With ageing, there is a change in the signal transduction 
of the beta receptor and negative regulation of the beta-adrenergic receptors, 
so that there may be a reduction in the effectiveness of beta-blocking agents at 
doses considered normal. The reduction in GFR causes a decrease in the capacity 
of diuretic and natriuretic responses. NSAIDs reduce the effects of diuretics, and 
there is a compromise in adaptive and homeostatic mechanisms, thus reducing the 
effectiveness of diuretics in doses considered normal, and a high risk of hypoka-
laemia, hypomagnesaemia and hyponatraemia may occur. NSAIDs can also reduce 
the effects of ACEI. Since older patients are more sensitive to warfarin, there is an 
increased risk of bleeding when taking anticoagulant drugs [10, 17].
The presence of comorbidities is also responsible for pharmacodynamic changes 
during the ageing process. For example, the presence of psychiatric disorders such 
as schizophrenia, depression and dementia can alter the function of several neu-
rotransmitters [16].
3. Polypharmacy and inappropriate medication in older patients
Pharmacotherapy can improve the quality of life, cure, prevent and relieve the 
symptoms of many pathologies. However, there is a growing concern that many older 
people are taking an inappropriately high number of medications [18]. Polypharmacy 
consists of the use of several drugs by the same patient and appears as a response 
to the increase in health-related problems, particularly in older adults. There is no 
consensual definition for polypharmacy; however, most studies consider the con-
sumption of five or more drugs per day per person [19]. In older patients, polyphar-
macy has been associated with a wide range of negative health outcomes, including 
falls, ADR effects, changes in physical and cognitive ability, hospital readmission and 
mortality. It has also been associated with increasing costs in health [4, 18].
Besides, older adults often self-medicate themselves to improve their quality of 
life. This is a concern because the use of home medicines and herbal products, as 
well as the diet, can interfere with their health, due to the many drug interactions 
that can occur [20].
The inappropriate use of medicines by older patients who suffer from multiple 
diseases is a public health problem due to its impact on morbidity, quality of life and 
the improper use of health resources. There is an increase in hospital readmissions 
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and the occurrence of ADR, leading the older patients to have difficulties in carry-
ing out their daily activities, progressively losing their autonomy and, consequently, 
with loneliness and social isolation [4, 21]. Polypharmacy and multiple comorbidi-
ties are also associated with a lack of therapeutic compliance by older patients. The 
non-adherence may represent a risk because adverse health outcomes could occur 
like hospitalization and mortality [22].
Polypharmacy represents a challenge for health professionals, and it is essential 
to improve patients’ knowledge about their medication because beliefs about drugs 
are a strong predictor of adherence. If the patient knows what medicines he is 
using, the reason for pharmacotherapy and believe about its benefit, the adherence 
problem will be improved. In practice, the main goal is to achieve an ideal pharma-
cotherapy by reducing the number of drug-related problems (DRP).
The probability of a drug interaction occurring also increases with ageing due to 
the higher number of drugs used by older patients. These interactions have nega-
tive effects on health, and therefore, health professionals must be alert to possible 
interactions and must prevent them from occurring [23].
Most of the medications are considered appropriate for older patients, as long as 
they are used in the correct dosage and for the period strictly necessary. However, 
since older adults are more susceptible to the adverse effects of drugs, as a result 
of changes on pharmacokinetics and pharmacodynamics, special care by health 
professionals is needed when treating older patients.
Having more than one prescriber increases the risk of inappropriate medications 
use. Thus, it is crucial to implement medication review procedures and that the 
most frailty older adults have a clinician with knowledge of all their pharmaco-
therapy and improve communication with caregivers [23].
Some studies have shown that some measures can be implemented to decrease 
polypharmacy and its adverse effects, improving the quality of the prescription, 
such as educational programmes for patients and professionals and the creation of 
multidisciplinary teams of health professionals [24].
4. Improve pharmacotherapy in older patients
To improve the pharmacotherapy in older patients, the available tools must be 
friendly to improve the use by the health professionals.
According to Wooten [25–27], 10 rules must be followed by the physician’s when 
prescribing, especially in older patients: (1) know the patient and use the patient’s 
most current medical record; (2) follow the tenets of evidence-based medicine, but 
understand the limitations of the evidence; (3) understand the potential pharmaco-
kinetic and pharmacodynamic changes that can occur in older adults, and use this 
specific patient information to make prudent prescribing decisions; (4) recognize 
and investigate patient factors that may contribute to medication problems; (5) 
avoid the prescribing cascade, if possible; (6) prescribe and recommend only those 
medications/drug classes for which have a thorough understanding of the pharma-
cology; (7) identify, anticipate and monitor potential drug interactions before they 
become a problem; (8) establish a monitoring plan for each medication prescribed 
for both efficacy and toxicity; (9) properly counsel patients/caregivers on all of 
the patient’s medications, and ensure that the patient understands the pharmaco-
therapy plan; and (10) assess and address compliance issues.
Clinical decision support includes a variety of tools and interventions that can be 
computerized or noncomputerized. Clinical decision support systems (CDSS) are char-
acterized as tools for information management and include several clinical guidelines. 
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In the last decades, the focus has been on tools to provide specific recommendations 
to patients, called advanced CDSS. These may include, for example, checking interac-
tions between drug-disease, drug-drug, individualized dosing support and advice on 
laboratory tests during drug treatment [28]. The creation and implementation of this 
type of tools are responsible for increasing the quality of care and improving health 
outcomes, reducing the likelihood of errors and adverse effects. Thus, it is possible to 
reduce uncertainty and increase the reproducibility of decisions, increasing efficiency, 
cost-effectiveness and the satisfaction of the patients and caregiver [29].
For reducing prescription errors in older patients, other measures can be taken, 
such as implementing an educational system to train prescription, especially in 
young doctors who have less practice, and also in hospitals, where this type of errors 
are more frequent [30]. In many hospitals, pharmacists are responsible for identify-
ing errors in the prescription of medications and must report them immediately to 
the medical team. Sometimes, the environment involving prescribing physicians 
may influence the prescription process, leading to some errors. So, all the conditions 
must be met so that the physician can carry out the prescription in the best possible 
way, making simple changes such as reducing background noise and promoting 
more effective communication between all health professionals and with patients. 
Upon admission of the older patients to the hospital, it is advisable to carry out a 
reconciliation of the medication in which all medicines used should be checked. 
The importance and suitability of each medicine for the patient should be assessed, 
as well as the needs of adding a new list with the latest medications, explaining 
reasons. This list must be updated and given to the next health professional respon-
sible for the patient [30]. There is currently a validated tool used to provide physi-
cians with a method for obtaining their patients’ medication history, the structured 
history taking of medication use (SHiM). The SHiM consists of 16 questions and 
reveals the potential to avoid discrepancies in patients’ medication histories [31].
Another way to improve pharmacotherapy for older patients is to use criteria 
that were created to identify PIM as tools to support clinical decision support as 
described above.
4.1  Criteria used as tools to reduce potentially inappropriate medications in the 
elderly
To reduce the use of PIM in older patients, strategies and tools have been 
developed in recent years to assess the appropriateness of medication use in this 
population. The created criteria can be classified as explicit, implicit or mixed. 
Explicit criteria are lists of drugs that can be applied with minimal information and 
clinical judgement. These do not consider individual differences between patients. 
In contrast, the implicit criteria consider the patient’s therapeutic regimen and are 
based on the judgement of a health professional, being specific to each patient. The 
mixed criteria, on the other hand, consist of a combination of the previous two, 
allowing to obtain advantages from both [8].
In 1991, Beers et al. [32] were the first ones to introduce the concept of PIM 
and to propose a list of PIM for the older adults. These criteria, developed to help 
healthcare professionals to assess the quality of prescription in older patients, were 
initially intended for psychiatric patients. In 2011, the American Geriatrics Society 
(AGS) assumed the responsibility for these criteria and became compromised 
to update them regularly, and in 2012 [33] the criteria were updated. After that, 
criteria have been updated, and new, improved versions appeared in 2015 [34] and 
recently in 2019 [35]. A consensus panel was created with several experts to define 
what these criteria would be and what individual aspects should be considered. 
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Figure 1. 
Flowchart of the operating procedure of the expected steps during prescription for older patients.
However, there are drugs not included in these criteria, and that may also be poten-
tially inappropriate for older patients.
Many other attempts have been proposed using implicit or explicit criteria. For 
example, the Medication Appropriation Index (MAI) measures the appropriation of 
prescriptions for elderly patients [36]. That is an implicit tool that consists of mak-
ing a structured assessment of the patient’s medications across 10 criteria worded as 
questions. The 10 items are essential to evaluate the potential of DRP.
Also, according to European standards, the EURO-FORTA List was created 
in 2018 and is based on the FORTA List that has been validated for Germany and 
Austria. The EURO-FORTA List is an implicit tool and consists of 264 drugs/drug 
classes organized in 26 groups according to clinical diagnosis or symptoms [37].
On the other hand, explicit tools, such as the Screening Tool to Alert to Right 
Treatment (START) and Screening Tool of Older Person’s Prescriptions (STOPP) 
criteria, originally created in 2008 [38], are adapted to European prescription 
standards. Over time, the START/STOPP criteria have been updated, with the most 
recent version (version 2) being published in 2015 [39]. These criteria are used 
as tools to help researchers and professionals to identify 81 PIM and 34 potential 
prescribing omissions (PPO). Although the STOPP criteria are classified as explicit, 
according to studies carried out recently in Portugal, for only 29 of the 81 STOPP 
criteria, a judgement can be made only with the patient’s medication profile infor-
mation. This means that 52 of the STOPP criteria require additional information 
(i.e., duration of treatment, previous medication, current medical conditions, 
medical history and laboratory data) [40].
In 2015, the EU (7)-PIM List, an explicit criteria tool, was developed by experts 
from seven European countries (Germany, Finland, Estonia, Holland, France, Spain 
and Sweden) that allows the identification and comparison of PIM in these coun-
tries [41]. The EU (7)-PIM List development process was based on the participation 
of several European experts in two Delphi rounds. Some PIM concepts were defined 
considering the dose, the time of use or the therapeutic scheme, and the final list 
consists of 282 PIM.
In addition to these criteria, there are many other PIM lists in several countries, 
such as LaRoche (France) [42, 43], the PRISCUS list (Germany) [44], the Austrian 
consensus panel list [45], the NORGEP criteria (Norway) [46] and the Canada 
national consensus panel list [47].
Figure 1 is a flowchart that represents the steps that must be taken by health 
professionals when prescribing medications to the elderly, including the moment 
when they should consult the currently available PIM identification criteria.
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5. Conclusions
There are many physiological and pathophysiological changes associated with 
ageing that can affect the disposition of a drug. However, there are many variations 
among individuals. Thus, health professionals should be more alert during a pre-
scription to older patients and monitor their health status with individual attention.
One of the main factors responsible for variability in older patients is genetics 
since the structure, function and expression of most of the enzymes involved in 
metabolism can be affected due to genetic polymorphism, which will modify the 
therapeutic effect of certain drugs. Thus, the concept of individualized therapy, 
which analyses for each subject, genetic and non-genetic factors to optimize 
the treatment for each patient according to their characteristics, is increas-
ingly common.
In general, older patients have a higher sensitivity to drug therapy, so recom-
mendations for the appropriate prescription of drugs in the elderly population 
should be considered.
The incorporation of the described criteria in the CDSS has been successful in 
the detection of PIM. Persistent changes in medication were recorded in 8.7% of the 
alerts generated [48]. These data suggest that CDSS alerts are a useful tool for imple-
menting guidelines related to the identification of PIM for older patients and for 
helping physicians during the prescription process, improving healthcare practices.
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ACEI angiotensin conversion enzyme inhibitors
ADR adverse drug reaction
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NSAIDs nonsteroidal anti-inflammatory drugs
PIM potentially inappropriate medication
PPO potential prescribing omissions
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A. Glossary
Adverse drug reactions A response to a medicinal product which is noxious and unintended [49]
Bioavailability The fractional extent to which a dose of drug reaches its site of action or a 
biological fluid from which the drug has access to its site of action [50]
Drug-related problems An event or circumstance involving drug therapy that actually or potentially 
interferes with desired health outcomes [51]
Pharmacodynamic Biochemical and physiological effects of drugs and their mechanisms of 
action [50]
Pharmacokinetic The absorption, distribution, metabolism and excretion of a drug that occurs 
since the moment when the drug enters the body [50]
Polypharmacy The concurrent use of multiple medications. Although there is no standard 
definition, polypharmacy is often defined as the routine use of five or more 
medications. This includes over-the-counter, prescription and/or traditional 
and complementary medicines used by a patient [52]
Potentially inappropriate 
medication
Medicines where the potential risk is greater than the potential benefit, 
especially when safer alternatives are available [41]
Prodrugs Inactive drug that undergo metabolism to an active drug [50]
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